Oral Probiotic Microcapsule Formulation Ameliorates Non-Alcoholic Fatty Liver Disease in Bio F1B Golden Syrian Hamsters

Abstract

The beneficial effect of a microencapsulated feruloyl esterase producing Lactobacillus fermentum ATCC 11976 formulation for use in non-alcoholic fatty liver disease (NAFLD) was investigated. For which Bio F1B Golden Syrian hamsters were fed a methionine deficient/choline devoid diet to induce non-alcoholic fatty liver disease. Results, for the first time, show significant clinical benefits in experimental animals. Examination of lipids show that concentrations of hepatic free cholesterol, esterified cholesterol, triglycerides and phospholipids were significantly lowered in treated animals. In addition, serum total cholesterol, triglycerides, uric acid and insulin resistance were found to decrease in treated animals. Liver histology evaluations showed reduced fat deposits. Western blot analysis shows significant differences in expression levels of key liver enzymes in treated animals. In conclusion, these findings suggest the excellent potential of using an oral probiotic formulation to ameliorate NAFLD.

Efficacy of probiotics in non‐alcoholic fatty liver disease in adult and children: A meta‐analysis of randomized controlled trials

“…5 Accumulation of cholesterol, especially derived from biosynthetic routes, alters the intracellular cholesterol transportation and homeostasis, thus leading to liver injury and steatosis, inflammation, and fibrosis. 21,22 The results of the current and previous studies 18,23 consistently support the notion that probiotics have an effect on reducing T-chol levels in NAFLD patients. The disturbance of lipid metabolism was present in NAFLD 24,25 and probiotics may effectively regulate the blood lipids to a beneficial direction in NAFLD patients.…”

Effects of Multistrain Probiotic Supplementation on Glycemic and Inflammatory Indices in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial

“…The role of the probiotics in NAFLD has been intensely evaluated during the last decade, and several studies in animal models emphasis on the important role of intestinal microbiota composition in NAFLD development and progression [15,16]. Although it is now well known that in humans, changes in microbiota composition are strongly associated with aminotransferases changes in NAFLD [17,18], limited clinical trials were found regarding the effects of probiotics on glycemic and inflammatory indices in patients with NAFLD.…”

“…In addition, probiotic consumption significantly decreased serum insulin, HOMA-IR, TNF-a, and IL-6 during 2 months. Bhathena et al [16] and Ritze et al [21] have recently found that probiotic may reduce insulin, insulin resistance, TNF-a, and IL-1b levels in rats with NAFLD. The present results, in agreement with other investigations in patients with diabetes or in animal models [14,22,23], suggested that probiotic supplementation may decrease insulin resistance and inflammatory parameters.…”

The Effect of Synbiotic Supplementation on Body Composition and Lipid Profile in Patients with NAFLD: A Randomized, Double Blind, Placebo-Controlled Clinical Trial Study

“…On the other hand, most of studies on the relationship between microbial flora and obesity observed significant changes in composition and metabolic function of gut microbiome in obese individuals (8,9). It seems that obesity is associated with certain intestinal microbiome, which have the ability to have more energy extraction from diet and cause more fatty acids uptake in the liver and peripheral tissues (10).…”